B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.

Snuderl, Matija

B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma. [electronic resource] - The American journal of surgical pathology Mar 2010 - 327-40 p. digital

Publication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't

1532-0979

10.1097/PAS.0b013e3181cd3aeb doi


Adolescent
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Burkitt Lymphoma--classification
Child
Drug Resistance, Neoplasm
Female
Gene Expression Regulation, Neoplastic
Gene Rearrangement, B-Lymphocyte, Heavy Chain
Genes, Immunoglobulin Heavy Chain
Humans
Immunophenotyping
In Situ Hybridization, Fluorescence
Kaplan-Meier Estimate
Karyotyping
Lymphoma, B-Cell--classification
Lymphoma, Large B-Cell, Diffuse--classification
Male
Middle Aged
Neoplasm Staging
Polymerase Chain Reaction
Predictive Value of Tests
Proportional Hazards Models
Proto-Oncogene Proteins c-bcl-2--genetics
Proto-Oncogene Proteins c-myc--genetics
Retrospective Studies
Risk Assessment
Terminology as Topic
Time Factors
Treatment Outcome
World Health Organization
Young Adult